Kornimate/medical-research-clean huggingface dataset:
evaluation of a twenty-session cognitive-behavioral therapy with anorexia nervosa (cbt-20-an) among adults (18+)

Conditions: Anorexia Nervosa

Summary: the study is a clinical trial assessing the efficacy of a new twenty session cognitive behavioral therapy for adults (18+) with anorexia nervosa (an). it is expected that participants will gain a significant amount of weight and experience a significant decrease in eating disorder psychopathology and behavior from pre- to post- treatment and that this will be retained after 6-months.


Eligibility criteria:
inclusion criteria: 1. eligible patients must meet dsm-5 criteria for anorexia nervosa. this diagnosis can be conferred via the ede 17.0d. 2. age \> 18 3. patients must be able to provide informed consent and comply with the study procedures. 4. patients must be able to complete computer-based self-report questionnaires with adequate accommodation, if necessary. 5. patients must have a primary care physician, adolescent medicine physician, or consulting physician with eating disorder expertise at massachusetts general hospital/massachusetts general brigham network who can provide ongoing medical monitoring while the patient takes part in the study. exclusion criteria: patients will be excluded if they exhibit: 1. bmi \ 19, obtained via patient medical chart or from study 2023p000469 or 2018p002915. 2. hr \ 100, obtained via patient medical chart or from study 2023p000469 or 2018p002915. 3. systolic bp (sbp and dbp) \ 160, obtained via patient medical chart or from study 2023p000469 or 2018p002915. 4. temperature \< 96.5 f, obtained via patient medical chart or from study 2023p000469 or 2018p002915. 5. not eating food by mouth and/or any tube feeding, per ede 6. purging \> 4x/week, per ede. 7. active suicidality (suicidal ideation with intent or plan) to the point that more intensive treatment (i.e. acute hospitalization) is required 8. active untreated and unstable bipolar disorder (i.e. stable bipolar disorder under care of a psychiatrist is allowed) 9. psychosis 10. intellectual disability 11. any condition that, after the baseline evaluation, is determined to preclude treatment with cbt. 12. concurrent psychotherapy. patients must be willing to take a pause from any ongoing psychotherapy in order to focus on cbt-an-20, which is in alignment with standard clinical care. 13. symptoms that are not appropriate for outpatient level of care and therefore require a higher level of care (i.e. bmi \<15 or purging more than 4x/week) 14. homicidal ideation 15. inability to speak english well enough to engage in cbt
estrogen receptor variants, hdl, and atherosclerosis

Conditions: Cardiovascular Diseases; Atherosclerosis; Coronary Arteriosclerosis; Heart Diseases

Summary: to measure the association between estrogen receptor variants and the extent of atherosclerosis in the thoracic and abdominal aorta and the right coronary artery in subjects in the pday study.

background: increased levels of hdl cholesterol are associated with lower rates of clinical and anatomic atherosclerosis, even in adolescents and young adults. in premenopausal women, estrogen-associated increases in hdl may account for their low rates of coronary heart disease (chd) events. recently, a sequence variant in the estrogen receptor-alpha (er-alpha) gene, er-alpha ivs1-397 t/c), has been linked to twofold greater increases in hdl cholesterol in response to hormone replacement therapy (hrt). however, it remains unclear whether this sequence variant also augments hdl levels in the setting of premenopausal estrogen exposure and whether such differences translate into greater reductions in atherosclerosis risk. the study uses the cohort of the pathobiology of atherosclerosis in youth (pday) study, a large cross-sectional autopsy study of the extent of atherosclerosis in subjects aged 15 to 34 years. the detailed descriptions of atherosclerotic lesions, combined with data on cardiovascular risk factors and access to tissue for dna extraction, makes this an ideal cohort in which to examine the association between er-alpha ivs1-397 genotypes, hdl levels, and development of early atherosclerosis. design narrative: the overall goal for this study is to measure the association between the estrogen receptor (er- ivs1-401 t/c) polymorphism and extent of abdominal aorta, thoracic artery, and right coronary artery atherosclerosis in pathobiological determinants of atherosclerosis in youth (pday) subjects. the investigators will use dna extracted from liver specimens in order to measure the er polymorphisms. the extent of atherosclerosis will be defined as the percent of intimal area involved with fatty streaks or raised lesions, using previously established pday definitions. however, percent involvement of fatty streaks alone and the percent involvement of the individual components of raised lesions (fibrous plaques, complicated lesions, and calcified lesions) will be analyzed separately. available data on risk factors (smoking, diabetes, hyperlipidemia, hypertension) will permit reducing confounding of the results by allowing adjustments for effects of the major risk factors for coronary heart disease. the department of pathology at louisiana state university health sciences center (lsuhsc) has been designated by the national heart, lung and blood institute to centralize, maintain, and distribute the valuable material collected through the combined efforts of the cooperating institutions for further studies in atherosclerosis. lsuhsc will provide dna for polymorphism analysis and assist in data analysis. polymorphism determination will occur at wake forest.

Eligibility criteria:
no eligibility criteria
the effect of viscous dietary fibers on ldl-cholesterol

Conditions: Cardiovascular Risk Factor; Hypercholesterolemia

Summary: this systematic review and meta-analysis is aimed to assess the effect of commonly consumed viscous fibers on blood lipids including ldl-c, non-hdl-c, and apob.

medline, embase, cinahl, and the cochrane central databases were searched through may 13, 2019. three independent reviews extracted data and assessed risk of bias. randomized controlled trials that assessed the effect of barley b-glucan, oat b-glucan, konjac glucomannan (kjm), psyllium, guar gum, and pectin, with a study duration of ≥ 3 weeks, in adults with or without hypercholesterolemia were included. data were pooled using the generic inverse variance method with random effects models and expressed as mean differences with 95% confidence intervals. heterogeneity was assessed by the cochran q statistic and quantified by i2 statistic. overall quality of the evidence was assessed using the grade (grading of recommendations assessment, development, and evaluation) approach.

Eligibility criteria:
inclusion criteria: * must be a randomized controlled clinical trial with either a parallel or cross-over design * have a treatment period of at least 3 weeks * hypercholesterolemic or normocholesterolemic adults, overweight and obese individuals or individuals with diabetes were all acceptable * sources from β-glucan oats, β-glucan barley, konjac, psyllium, guar gum, and pectin were accepted * the amount of soluble fiber must be reported or measured or must be computable. * must be appropriately controlled. * must measure one of ldl-c, non-hdl-c or apob. these lipid measures can be either primary or secondary outcomes. * enough information must be provided to calculate the magnitude of effect, i.e. end of treatment measures and/or change from baseline measures exclusion criteria: * if the study was insufficiently controlled, i.e. the control was another soluble fiber * if the soluble fiber was a combination supplement or in whole food sources where the amount of soluble fiber could not be isolated * if the outcome measures did not include ldl-c, non-hdl-c or apob * if the treatment period was less than 3 weeks * if the study was from a non-adult population * if the study provided insufficient information to calculate a magnitude of effect * secondary information such as reviews, editorials, commentaries, were excluded * if the dose was less than 0.4g/day

Keywords: viscous fiber barley b-glucan oat b-glucan konjac glucomannan psyllium guar gum pectin
phase 1 study of lop628 in adult patients with ckit-positive solid tumors and acute myeloid leukemia

Conditions: cKIT-positive Solid Tumors; AML

Summary: lop628 is an antibody-drug conjugate (adc) consisting of an anti-ckit humanized igg1/κ antibody conjugated to a maytansine payload via a non-cleavable linker. lop628 provides an opportunity to target ckit overexpressing tumors.


Eligibility criteria:
inclusion criteria: for patients with solid tumors: * documented ckit-positive neoplasms * patient must have progressive disease as defined by any of the following: * sclc: patient has progressed after at least 1 prior therapy * gist : patient has relapsed or has refractory disease, and no further approved effective therapeutic option exists * patients with other ckit-positive solid tumors: patient has progressed after at least one prior line of therapy and no further approved effective therapeutic option exists * patient has measurable disease as per recist v1.1 criteria for patients with aml: * documented ckit-positive acute myelogenous leukemia * consent to newly obtained bone marrow aspirate * patient must have progressive disease defined as relapsed or refractory non-pml aml following standard therapy or for whom no effective therapy exists. * blast count \< 50,000/mm3 exclusion criteria: for patients with solid tumors: * patient has central nervous system (cns) metastatic involvement unless the cns metastases have been previously treated and the patient is clinically stable and on a stable dose of corticosteroids for at least 4 weeks prior to enrollment. * patient has the presence of other clinically significant hematologic, cardiac, respiratory, gastrointestinal, renal, hepatic or neurological conditions. * patient has a history of serious allergic reactions, which in the opinion of the investigator may pose an increased risk of serious infusion reactions * patient has been previously treated with ckit directed antibodies * pregnant or nursing women for patients with aml: * patient has received prior allogeneic bone marrow transplant (bmt). * patient has the presence of other clinically significant cardiac, respiratory, gastrointestinal, renal, hepatic or neurological disease * patient has a history of serious allergic reactions, which in the opinion of the investigator may pose an increased risk of serious infusion reactions * patient has been previously treated with ckit directed antibodies * pregnant or nursing women

Keywords: lop628, ckit, adc, antibody drug conjugates, maytansine
impairment in glucose homeostasis among obese adolescents in high risk diabetes prone population - jisr az-zarqa village

Conditions: Glucose Metabolism Disorders

Summary: obesity is increasing all over the world in adults, adolescents and children,and is followed by morbidity, including the metabolic syndrome. hypothesis: among obese adolescents there is a subgroup with impaired glucose homeostasis the aim of the study is to identify adolescents with impaired glucose metabolism, 12-18 years, among high risk diabetes prone population, for diagnosis and treatment.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of obesity exclusion criteria: * history of disease or drug therapy affecting glucose metabolism
evaluation of serum scube-1 scube-2 and scube-3 levels in patients with polikistik over syndrome ,

Conditions: Polycystic Ovary Syndrome

Summary: the aim of this study is to investigate serum scube-1 and scube-3 levels in pcos and non-pcos cases compared with non-pcos healthy controls with similar age and body mass index

the aim of this study was to investigate serum scube1 and scube3 levels in pcos and non-pcos cases compared with non-pcos healthy controls with similar age and body mass index. this will be a prospective clinical laboratory study,it will include women with pcos diagnosis (according to the 2003 rotherdam criteria). 40 cases of reproductive age will be included in the study group, which will be included in the survey after being approved for participation in the survey from field trials. forty patients who will not have any complaints between the ages of 18-35 who will apply to the gynecology policlinic as a control group but who had no pcos o rany other systemic problems and will be similar in terms of age group and body mass index will be included in the study after being approved for participation in the study. from the study and control group, 5 ml of blood will be taken from the untreated biochemical tube for serum scube1 scube2 scube3. the blood samples will be centrifuged at 1000 g for 10 minutes and the serum fraction will be obtained and the serum will be stored at -80 ° c to be stored until the day of the tube operation. serum scube1, scube2 scube3 levels will be measured using elisa kits. ,

Eligibility criteria:
inclusion criteria * clinical diagnosis of pcos * 18-35 years old exclusion criteria * endocrinopathies (including diabetes mellitus, hyperprolactinemia, cushing's disease and congenital adrenal hyperplasia), systemic disease (eg asthma), collagen disorder, hypercholesterolemia, sickle cell anemia or neoplasm, * coronary artery disease , angina or myocardial infarction, or any known vascular, infectious, or inflammatory disease, including hypertension, coronary arterioscitis, and electrocardiographic changes; * use of any medication (e.g., insulin sensitizing drugs, oral contraceptives, antiandrogens, statins, aspirin, corticosteroids and gonadotropin releasing hormone agonists and antagonists) within the previous 3 months; * abnormal serum albumin concentration (normal concentration, 30-55 g / l), * abnormal troponin i concentration, * present smoker, * abnormal renal, hepatic and thyroid function test results; * refusing to participate in the work.

Keywords: pcos scube cardiovascular disease
the edmonton symptom assessment system (esas) as a screening tool for depression in cancer pain patients

Conditions: Screening Tool for Depresion in Cancer Pain Patients

Summary: compare thai versions of the edmonton symptom assessment system (esas) and the hospiral anxiety and depression scale (hads) with diagnostic and statistical manual (dsm-5), as a screening tool for depression in cancer pain patients


Eligibility criteria:
inclusion criteria: * cancer patients who follow up as out patient at pain clinic, siriraj hospital * age older than 18 years old * fluently read, write and speak in thai language * no cognitive impairment exclusion criteria: * unstable clinical presentation * severe pain or pain numerical rating scale more than 7 * severe associated symptoms such as nausea, vomiting * the patient who do not know their diagnosis
a study of ripretinib vs sunitinib in patients with advanced gist with specific kit exon mutations who were previously treated with imatinib

Conditions: GIST

Summary: this is a phase 3, 2-arm, randomized, open-label, global, multicenter study comparing the efficacy of ripretinib to sunitinib in participants with gist who progressed on first-line treatment with imatinib, harbor co-occurring kit exons 11+17/18 mutations, and are without kit exon 9, 13, or 14 mutations. upon disease progression as determined by an independent radiologic review, participants randomized to sunitinib will be given the option to either crossover to receive ripretinib 150 mg qd or discontinue sunitinib.


Eligibility criteria:
inclusion criteria: 1. male or female ≥18 years of age. 2. histologic diagnosis of gist with co-occurring kit exons 11+17/18 mutations confirmed by ctdna sample. 3. participants must have advanced gist and radiologic progression on imatinib treatment. 4. eastern cooperative oncology group (ecog) performance status (ps) of ≤2 at screening. 5. female participants of childbearing potential must have a negative pregnancy test at screening and prior to the first dose of study drug. 6. participants of reproductive potential must agree to follow contraception requirements. 7. participants must have at least 1 measurable lesion according to mrecist v1.1 within 21 days prior to the first dose of study drug. 8. adequate organ function and bone marrow reserve based on laboratory assessments performed at screening. exclusion criteria: 1. history of kit exon 9 mutation or detection of kit exon 9, 13, or 14 mutations in a ctdna sample. 2. has known active central nervous system metastases. 3. new york heart association class ii-iv heart disease, myocardial infarction within 6 months of cycle 1 day 1, active ischemia or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiac arrhythmia requiring therapy, uncontrolled hypertension, or congestive heart failure. 4. use of strong or moderate inhibitors or inducers of cytochrome p450 (cyp) 3a prior to the first dose of study drug, and consumption of grapefruit or grapefruit juice within 14 days prior to the first dose of study drug. 5. major surgeries (eg, abdominal laparotomy) within 4 weeks of the first dose of study drug. 6. known human immunodeficiency virus or hepatitis c infection only if the participant is taking medications that are excluded per protocol, acute or chronic hepatitis b, or acute or chronic hepatitis c infection. 7. gastrointestinal abnormalities including, but not limited to: 1. inability to take oral medication 2. malabsorption syndromes 3. requirement for intravenous alimentation 8. any active bleeding excluding hemorrhoidal or gum bleeding.

Keywords: advanced gastrointestinal tumors gastrointestinal stromal tumors imatinib ripretinib
spinal anesthesia and peri-operative opioid consumption in open abdominal prostatectomy

Conditions: Pain, Postoperative; Opioid Use; Analgesia

Summary: retrospective analysis to assess the impact of spinal anesthesia on peri-operative opioid consumption during open abdominal prostatectomy. the authors compare the group that had spinal anesthesia in combination with propofol sedation and a laryngeal mask to the second group that underwent the same procedure in general anesthesia with tracheal intubation.

retrospective analysis to assess the impact of spinal anesthesia on peri-operative opioid consumption during open abdominal prostatectomy. the authors compare the group that had spinal anesthesia in combination with propofol sedation and a laryngeal mask to the second group that underwent the same procedure in general anesthesia with tracheal intubation. ...

Eligibility criteria:
inclusion criteria: * elective, radical abdominal prostatectomy * \>18 years exclusion criteria: * chronic pain therapy (e.g. out-of-hospital opioid therapy) * laparoscopic approach
a study to evaluate the safety and pharmacokinetics of ad-221 compared to coadministration of ad-221a and ad-221b

Conditions: Hyperlipidemias

Summary: primary endpoint of this study is to evaluate the pharmacokinetic characteristics of ad-221 in healthy male subjects.

the purpose of this study is to evaluate the pharmacokinetic characteristics and safety profiles of ad-221 compared with coadministration ad-221a and ad-221b in healthy male subjects.

Eligibility criteria:
inclusion criteria: * body weight equal to or greater than 50kg and body mass index (bmi) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit * the age equal to or greater than 19 in healthy volunteers at the time of screening visit exclusion criteria: * presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in digestive system, neuropsychiatric system, endocrine system, liver, cardiovascular system * subjects who judged ineligible by the investigator
anterior vs. posterior quadratus lumborum block in nephrectomy patients

Conditions: Quadratus Lumborum Block

Summary: * primary outcome: to compare the efficacy of anterior subcostal versus posterior approach in ultrasound guided quadratus lumborum block. * secondary outcome: to evaluate the efficacy of quadratus lumborum block in the control of postoperative pain in patients undergoing nephrectomy surgery, hemodynamics, any complications and patients' satisfaction..

a variant of the ultrasound-guided transversus abdominis plane (tap) block was first described in an abstract, in which local anesthetic injection occurs at the point where the internal oblique and transversus abdominis muscles taper off and adjoin the lateral border of quadratus lumborum (ql) muscle. currently, the ql block is performed as one of the perioperative pain management procedures for all generations (pediatrics, pregnant, and adult) undergoing abdominal surgery. however, there is large disagreement regarding the best approach for administering the block because of unclear mechanisms responsible for the effects and complicated nomenclature system. nephrectomy for patients with renal cell carcinoma (rcc) was first described in 1969. surgical treatment varies with the pathology. simple nephrectomy is the preferred option for those with non-neoplastic disease (e.g. trauma, non-functioning kidney with chronic infection) with radical nephrectomy being preferred in those with neoplastic disease. radical nephrectomy implies resection of the whole of gerota's fascia, including the perinephric fat, lymphatics, and the ipsilateral adrenal gland. here the investigators are going to compare the anterior (subcostal) approach to the posterior approach to determine their level of spread and their value in controlling postoperative pain in patients scheduled for nephrectomy surgery.

Eligibility criteria:
inclusion criteria: * both sex * age: 18-60 years. * asa i and ii * elective surgery exclusion criteria: * patient's refusal. * allergy to local anesthetics. * peripheral neuropathy. * bleeding diathesis. * inflammation or infection over injection site. * morbid obesity. * patients on previous opioid therapy. * psychiatric disorders. * emergency surgery